Reported its financial results for the fiscal year ended December 31, 2023. Net losses for the fourth ...
Will release its full-year and fourth-quarter 2023 financial results before the opening of the U.S. ...
Will release its first-quarter 2023 financial results before the opening of the U.S. financial markets ...
Today reported its financial results for the fiscal year ended December 31, 2022. Net losses for the ...
Announced that the U.S. Food and Drug Administration has granted Orphan Drug Exclusivity to PEDMARK® ...
Reported its financial results for the fiscal quarter ended September 30. Net loss for the three months ...
Today announced the U.S. commercial launch and availability of PEDMARK® (sodium thiosulfate injection) ...
Today announced that the U.S. Food and Drug Administration has approved PEDMARK®, a sodium thiosulfate ...
~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of...
RESEARCH TRIANGLE PARK, N.C., June 14, 2022 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that...